ERC Advanced Grant · 2018
Targeting RAS driven tumour immune evasion
Mutations in RAS oncogenes are responsible for driving some 20% of all human malignancies, occurring in many major killers, such as lung, pancreatic, and colon cancers, but attempts to develop therapeutic interventions for RAS mutant cancers have yet to provide clinical benefit. By inhibiting pathways downstream of RAS along with other key signaling nodes, we have developed combination therapies that cause major regression of KRAS mutant lung cancer in mouse models. However, a major limitation is that the tumours are not eradicated and rapidly recur once treatment is withdrawn. Lung cancer is partly responsive to immunotherapies in the clinic, suggesting dependence on immune evasive…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.